RNA

Avidity Biosciences Inc

Add to Watchlist

Advanced Chart

36.270

+3.06(9.214%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

37.590

Open

33.500

VWAP

35.91

Vol

6.08M

Mkt Cap

4.37B

Low

32.720

Amount

218.36M

EV/EBITDA(TTM)

Total Shares

107.77M

2.99B

EV/OCF(TTM)

P/S(TTM)

495.84

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.60M

-46.07%

-1.104

+37.96%

1.60M

-31.4%

-1.024

+57.55%

1.61M

-21.5%

-0.956

+47.05%

Estimates Revision

The market is revising Downward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by -12.9% over the past three months. During the same period, the stock price has changed by 16.23%.

Revenue Estimates for FY2025

Revise Downward

-12.9%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.21%

In Past 3 Month

Stock Price

Go Up

+16.23%

In Past 3 Month

16 Analyst Rating

84.89% Upside

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 67.06 USD with a low forecast of 50.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

0 Hold

0 Sell

Strong Buy

84.89% Upside

Current: 36.270

Low

50.00

Averages

67.06

High

96.00

84.89% Upside

Current: 36.270

Low

50.00

Averages

67.06

High

96.00

Evercore ISI

Gavin Clark-Gartner

Outperform

maintain

$60 -> $70

2025-07-11

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

$60 -> $70

2025-07-11

maintain

Outperform

Reason

Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on Avidity Biosciences to $70 from $60 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

Goldman Sachs

NULL

Buy

initiated

$55

2025-07-10

Reason

Goldman Sachs

Price Target

$55

2025-07-10

initiated

NULL

Buy

Reason

Goldman Sachs resumed coverage of Avidity Biosciences with a Buy rating and $55 price target. The firm expects clarity over the next 12-18 months on the company's regulatory outlook.

Bernstein

Outperform

initiated

$50

2025-06-24

Reason

Bernstein

Price Target

$50

2025-06-24

initiated

Outperform

Reason

Wolfe Research

Andy Chen

Outperform

initiated

$55

2025-06-18

Reason

Wolfe Research

Andy Chen

Price Target

$55

2025-06-18

initiated

Outperform

Reason

Wolfe Research

NULL -> Outperform

initiated

$55

2025-06-17

Reason

Wolfe Research

Price Target

$55

2025-06-17

initiated

NULL -> Outperform

Reason

Wolfe Research initiated coverage of Avidity Biosciences with an Outperform rating and $55 price target.

Barclays

Overweight

maintain

$57 -> $59

2025-06-10

Reason

Barclays

Price Target

$57 -> $59

2025-06-10

maintain

Overweight

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Avidity Biosciences Inc (RNA.O) is -7.90, compared to its 5-year average forward P/E of -7.87. For a more detailed relative valuation and DCF analysis to assess Avidity Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.87

Current PE

-7.90

Overvalued PE

-3.46

Undervalued PE

-12.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.67

Current EV/EBITDA

-4.96

Overvalued EV/EBITDA

-1.07

Undervalued EV/EBITDA

-8.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

212.68

Current PS

628.80

Overvalued PS

393.71

Undervalued PS

31.66

Financials

Annual

Quarterly

FY2025Q1

YoY :

-55.60%

1.57M

Total Revenue

FY2025Q1

YoY :

+70.39%

-131.52M

Operating Profit

FY2025Q1

YoY :

+68.14%

-115.77M

Net Income after Tax

FY2025Q1

YoY :

+13.92%

-0.90

EPS - Diluted

FY2025Q1

YoY :

+80.35%

-128.58M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+209.26%

-4.09K

FCF Margin - %

FY2025Q1

YoY :

+278.72%

-7.36K

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 360.31% over the last month.

Sold

0-3

Months

1.1M

USD

3-6

Months

3.3M

USD

6-9

Months

11.0M

USD

0-12

Months

15.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

650.0K

Volume

6-9

Months

456.5K

Volume

0-12

Months

524.0K

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.8M

Volume

Months

6-9

2.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 360.31% over the last month.

Sold

0-3

Months

1.1M

USD

3-6

Months

3.3M

USD

6-9

Months

11.0M

USD

0-12

Months

15.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RNA News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

09:06:43

Avidity Biosciences receives FDA BTD for delpacibart zotadirsen

2025-07-17 (ET)

2025-07-17

11:58:09

Avidity, Phathom mentioned as potential takeout targets at Needham

2025-06-09 (ET)

2025-06-09

15:18:19

Avidity data strengthens accelerated approval case, says H.C. Wainwright

News

9.0

15:03 PMYahoo Finance

PinnedAvidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation

9.0

07-23NASDAQ.COM

Avidity Biosciences On Track To Seek Approval For Del-zota In DMD By Year-End

9.0

07-23PRnewswire

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping